These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

789 related items for PubMed ID: 19239686

  • 1. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
    Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE.
    Breast Cancer Res; 2009; 11(1):R11. PubMed ID: 19239686
    [Abstract] [Full Text] [Related]

  • 2. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J, Kanomata N, Yamashita T, Shimo T, Mizutoh A, Moriya T, Sonoo H.
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [Abstract] [Full Text] [Related]

  • 3. Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.
    Luhtala S, Staff S, Tanner M, Isola J.
    Tumour Biol; 2016 Jul; 37(7):9813-23. PubMed ID: 26810187
    [Abstract] [Full Text] [Related]

  • 4. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
    Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R.
    Cancer; 2006 Aug 15; 107(4):696-704. PubMed ID: 16826579
    [Abstract] [Full Text] [Related]

  • 5. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [Abstract] [Full Text] [Related]

  • 6. Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.
    Ulas A, Kos T, Avci N, Cubukcu E, Olmez OF, Bulut N, Degirmenci M.
    Asian Pac J Cancer Prev; 2015 Aug 01; 16(4):1643-9. PubMed ID: 25743846
    [Abstract] [Full Text] [Related]

  • 7. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
    Park SS, Kim SW.
    Oncol Rep; 2007 Jul 01; 18(1):139-43. PubMed ID: 17549359
    [Abstract] [Full Text] [Related]

  • 8. Risk factors and survival outcome in cerebral metastatic breast cancer.
    Bachmann C, Schmidt S, Staebler A, Schittenhelm J, Wallwiener D, Grischke EM.
    Med Oncol; 2014 Mar 01; 31(3):862. PubMed ID: 24504842
    [Abstract] [Full Text] [Related]

  • 9. Om.breast cancer in very young women aged 25 year-old or below in the center of Tunisia and review of the literature.
    Ben Abdelkrim S, Fathallah K, Rouatbi R, Ayachi M, Hmissa S, Mokni M.
    Pathol Oncol Res; 2015 Jul 01; 21(3):553-61. PubMed ID: 25962349
    [Abstract] [Full Text] [Related]

  • 10. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.
    Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN, Yu D.
    Am J Pathol; 2010 Oct 01; 177(4):1647-56. PubMed ID: 20813970
    [Abstract] [Full Text] [Related]

  • 11. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
    Eggemann H, Ignatov T, Burger E, Kantelhardt EJ, Fettke F, Thomssen C, Costa SD, Ignatov A.
    Endocr Relat Cancer; 2015 Oct 01; 22(5):725-33. PubMed ID: 26187126
    [Abstract] [Full Text] [Related]

  • 12. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.
    Ibrahim T, Farolfi A, Scarpi E, Mercatali L, Medri L, Ricci M, Nanni O, Serra L, Amadori D.
    Oncology; 2013 Oct 01; 84(3):150-7. PubMed ID: 23257904
    [Abstract] [Full Text] [Related]

  • 13. The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.
    Sujarittanakarn S, Himakhun W, Worasawate W, Prasert W.
    Asian Pac J Cancer Prev; 2020 Jun 01; 21(6):1559-1565. PubMed ID: 32592349
    [Abstract] [Full Text] [Related]

  • 14. Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy.
    Larsen MS, Bjerre K, Lykkesfeldt AE, Giobbie-Hurder A, Laenkholm AV, Henriksen KL, Ejlertsen B, Rasmussen BB.
    Breast; 2012 Oct 01; 21(5):662-8. PubMed ID: 22854050
    [Abstract] [Full Text] [Related]

  • 15. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
    Arapantoni-Dadioti P, Valavanis C, Gavressea T, Tzaida O, Trihia H, Lekka I.
    J BUON; 2012 Oct 01; 17(2):277-83. PubMed ID: 22740206
    [Abstract] [Full Text] [Related]

  • 16. Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss.
    Bogina G, Bortesi L, Marconi M, Venturini M, Lunardi G, Coati F, Massocco A, Manfrin E, Pegoraro C, Zamboni G.
    Virchows Arch; 2011 Jul 01; 459(1):1-10. PubMed ID: 21643691
    [Abstract] [Full Text] [Related]

  • 17. Expression of AIB1 protein as a prognostic factor in breast cancer.
    Lee K, Lee A, Song BJ, Kang CS.
    World J Surg Oncol; 2011 Oct 29; 9():139. PubMed ID: 22035181
    [Abstract] [Full Text] [Related]

  • 18. Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.
    Linderholm B, Bergqvist J, Hellborg H, Johansson U, Linderholm M, von Schoultz E, Elmberger G, Skoog L, Bergh J.
    Med Oncol; 2009 Dec 29; 26(4):480-90. PubMed ID: 19130322
    [Abstract] [Full Text] [Related]

  • 19. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
    Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ.
    Clin Cancer Res; 2005 Mar 15; 11(6):2163-8. PubMed ID: 15788662
    [Abstract] [Full Text] [Related]

  • 20. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
    Buta M, Džodić R, Đurišić I, Marković I, Vujasinović T, Markićević M, Nikolić-Vukosavljević D.
    Tumour Biol; 2015 Sep 15; 36(10):8193-200. PubMed ID: 25994573
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.